ReviewAntioxidants (Basel, Switzerland)2026
Gut Microbiota-Host Redox Crosstalk: Molecular Mechanisms, Disease Pathogenesis, and Therapeutic Interventions.
Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The crosstalk between the gut microbiota and the host redox system is essential for maintaining intestinal homeostasis and systemic health. Disruption of this bidirectional interaction impairs redox balance, promotes oxidative stress, and contributes to the initiation and progression of a wide range of diseases, including inflammatory bowel disease, metabolic liver disease, neurodegenerative disorders, and chronic kidney disease. In this review, we comprehensively summarize the molecular mechanisms by which the gut microbiota regulates host redox homeostasis, focusing on microbial metabolites, immune signaling, and host antioxidant pathways. We also discuss emerging mechanisms underlying microbiota-host redox interactions, including extracellular vesicle (EV)-mediated interkingdom communication, microbiota-driven regulation of intestinal epithelial ferroptosis, and microbial metabolic reprogramming. Furthermore, we highlight how gut microbiota dysbiosis extends oxidative stress beyond the intestine through the gut-liver, gut-brain, and gut-kidney axes, thereby driving the development of multiple organ diseases. Finally, we summarize recent advances in microbiota-targeted therapies and engineered bacterial EVs as innovative strategies for restoring redox homeostasis, and discuss their potential for the precision prevention and treatment of oxidative stress-associated diseases as well as the development of next-generation microbiome-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.